Jeffrey Schlom Selected Research

Carcinoembryonic Antigen

9/2017	Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein.
11/2015	Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.
10/2015	The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
11/2011	A pilot safety trial investigating a vector-based vaccine targeting carcinoembryonic antigen in combination with radiotherapy in patients with gastrointestinal malignancies metastatic to the liver.
4/2009	The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.
2/2009	Human dendritic cell maturation and activation by a heat-killed recombinant yeast (Saccharomyces cerevisiae) vector encoding carcinoembryonic antigen.
8/2008	Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects.
7/2008	The use of chelated radionuclide (samarium-153-ethylenediaminetetramethylenephosphonate) to modulate phenotype of tumor cells and enhance T cell-mediated killing.
5/2008	Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma.
9/2007	The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jeffrey Schlom Research Topics

Disease

199	Neoplasms (Cancer) 01/2022 - 01/2002
48	Carcinoma (Carcinomatosis) 01/2022 - 09/2002
41	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 01/2002
24	Vaccinia 01/2020 - 01/2002
19	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2003
18	Fowlpox 01/2018 - 10/2002
10	Breast Neoplasms (Breast Cancer) 01/2021 - 08/2010
8	Colorectal Neoplasms (Colorectal Cancer) 11/2022 - 09/2002
8	Chordoma 01/2021 - 03/2015
7	Infections 01/2021 - 07/2004
6	Adenocarcinoma 10/2015 - 01/2002
5	Human Influenza (Influenza) 01/2021 - 09/2007
5	Urinary Bladder Neoplasms (Bladder Cancer) 11/2019 - 08/2009
4	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 09/2002
4	Necrosis 01/2021 - 04/2014
4	Lung Neoplasms (Lung Cancer) 01/2020 - 06/2008
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 09/2002
4	Disease Progression 10/2019 - 02/2006
4	Communicable Diseases (Infectious Diseases) 05/2016 - 01/2008
4	Ovarian Neoplasms (Ovarian Cancer) 11/2011 - 09/2002
3	Squamous Cell Carcinoma of Head and Neck 01/2022 - 03/2006
3	Sarcoma (Soft Tissue Sarcoma) 01/2022 - 10/2015
3	COVID-19 01/2021 - 10/2020
3	Mesothelioma 11/2016 - 09/2005
3	Hematologic Neoplasms (Hematological Malignancy) 02/2014 - 08/2008
3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/2010 - 11/2005
2	Inflammation (Inflammations) 01/2022 - 01/2020
2	Papillomavirus Infections 01/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

118	VaccinesIBA 11/2022 - 01/2002
58	AntigensIBA 06/2021 - 01/2002
31	Cancer VaccinesIBA 01/2022 - 09/2002
27	Carcinoembryonic AntigenIBA 09/2017 - 01/2002
23	Proteins (Proteins, Gene)FDA Link 01/2022 - 03/2004
20	Monoclonal AntibodiesIBA 01/2020 - 05/2002
19	Brachyury protein (Brachyury)IBA 01/2021 - 04/2007
19	Prostate-Specific Antigen (Semenogelase)IBA 01/2021 - 01/2002
18	avelumabIBA 11/2022 - 10/2015
17	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 01/2002
17	Immunoglobulin G (IgG)IBA 01/2021 - 04/2002
15	Peptides (Polypeptides)IBA 01/2021 - 01/2002
14	Interleukin-12 (IL 12)IBA 01/2022 - 08/2009
14	PROSTVACIBA 01/2021 - 02/2011
14	Transcription Factors (Transcription Factor)IBA 01/2021 - 04/2007
13	EpitopesIBA 01/2017 - 01/2002
12	Interleukin-15 (Interleukin 15)IBA 01/2022 - 03/2007
11	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
11	CytokinesIBA 01/2021 - 12/2007
11	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 09/2017 - 10/2002
9	LigandsIBA 01/2022 - 10/2012
9	Docetaxel (Taxotere)FDA Link 01/2021 - 02/2006
9	AutoantigensIBA 11/2017 - 01/2002
8	B7-H1 AntigenIBA 01/2022 - 01/2018
8	CD58 Antigens (LFA-3)IBA 09/2017 - 10/2002
7	AntibodiesIBA 01/2021 - 04/2006
7	B7 AntigensIBA 08/2019 - 10/2002
6	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 10/2007
6	AndrogensIBA 01/2021 - 10/2002
6	ALT-803IBA 01/2021 - 09/2017
6	Granzymes (Granzyme)IBA 01/2020 - 08/2007
6	Biological ProductsIBA 01/2016 - 06/2004
5	Histone Deacetylase InhibitorsIBA 01/2022 - 01/2018
5	entinostat (MS 275)IBA 01/2022 - 01/2018
5	PerforinIBA 01/2017 - 09/2002
5	Interleukin-2 (IL2)IBA 12/2016 - 05/2003
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2016 - 05/2003
5	HLA-A2 Antigen (HLA A2 Antigen)IBA 12/2014 - 03/2004
4	Transforming Growth Factor beta (TGF-beta)IBA 01/2021 - 11/2009
4	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2019
4	Tamoxifen FDA LinkGeneric 01/2021 - 10/2013
4	Glycoproteins (Glycoprotein)IBA 01/2017 - 09/2002
4	Messenger RNA (mRNA)IBA 05/2014 - 01/2002
4	IpilimumabIBA 04/2014 - 02/2007
4	Hormones (Hormone)IBA 07/2008 - 08/2005
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2017
3	Interferon-gamma (Interferon, gamma)IBA 01/2022 - 09/2002
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 02/2021 - 03/2010
3	Papillomavirus Vaccines (HPV Vaccines)IBA 01/2021 - 01/2020
3	smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordicIBA 01/2021 - 08/2019
3	Chimeric Antigen ReceptorsIBA 01/2021 - 01/2017
3	Histones (Histone)IBA 01/2021 - 01/2019
3	Cetuximab (Erbitux)FDA Link 01/2020 - 12/2016
3	Therapeutic UsesIBA 11/2019 - 03/2005
3	InterleukinsIBA 04/2018 - 03/2007
3	Radioisotopes (Radionuclides)IBA 01/2016 - 04/2002
3	Pharmaceutical PreparationsIBA 01/2014 - 05/2004
3	Synthetic Vaccines (Recombinant Vaccines)IBA 10/2013 - 12/2007
3	CD40 Ligand (CD40L)IBA 10/2012 - 07/2004
3	ChitosanIBA 09/2010 - 03/2007
3	lymphotactinIBA 08/2007 - 11/2003
2	Bevacizumab (Avastin)FDA Link 11/2022 - 07/2016
2	Testosterone (Sustanon)FDA Link 04/2022 - 01/2021
2	Immunomodulating AgentsIBA 12/2021 - 01/2021
2	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 05/2016
2	EnzymesIBA 01/2021 - 05/2004

Therapy/Procedure

87	Therapeutics 01/2022 - 01/2002
65	Immunotherapy 11/2022 - 01/2002
17	Drug Therapy (Chemotherapy) 01/2021 - 09/2002
13	Castration 01/2021 - 07/2008
11	Radiotherapy 01/2021 - 05/2005
4	Radioimmunotherapy 04/2006 - 04/2002